IL2 and neoplasm: Rahman et al. investigated this approach in a preclinical PDAC model, demonstrating that T-cell receptor alpha-beta (TCRαβ)-depleted NK/macrophage-enriched cell therapy, stimulated with IL-2 and zoledronic acid, significantly enhances PDAC cell-killing when combined with tumor-specific monoclonal antibodies and radiation therapy [194].